Evaluation of a novel electrochemical detection method for Chlamydia trachomatis: application for point-of-care diagnostics.
Atlas Genetics has developed a point-of-care device for Chlamydia trachomatis utilizing a novel electrochemical detection principle. The assay has a time-to-result of less than 25 min. An independent preclinical validation study using 306 pretyped clinical samples determined a clinical sensitivity of 98.1% and specificity of 98.0%.
Atlas Genetics Ltd., Trowbridge,Wiltshire, BA14 0XG, UK. david.pearce@atlasgenetics.com
David M
DM
Pearce
Daniel P
DP
Shenton
Jeffrey
J
Holden
Charlotte A
CA
Gaydos
D002690:Chlamydia Infections / Q000175:diagnosis / Q000382:microbiology; D002692:Chlamydia trachomatis / Q000235:genetics / Q000302:isolation & purification*; D055664:Electrochemical Techniques / Q000295:instrumentation*; D006801:Humans; D046210:Microfluidic Analytical Techniques / Q000295:instrumentation*; D019095:Point-of-Care Systems; D016133:Polymerase Chain Reaction / Q000295:instrumentation; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity